SAN DIEGO (BUSINESS WIRE) Apros Therapeutics, Inc., a clinical stage biotechnology company focused on tissue-targeted Toll-Like Receptor 7 (TLR7) agonists for the treatment of advanced cancers and infectious diseases, today announced that they will present interim pharmacokinetic and pharmacodynamic Phase 1 clinic.
Dr. Erik Ranheim, an academic physician with a distinguished record of achievement in medical education, will be the next chair of the University of Wisconsin S
Press Release 30 September 2021 Immunicum Appoints New Experts in Cancer Immunology to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) today announced the appointment of Ada M.